Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of M701 in Malignant Ascites
NCT04501744Phase 1Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of M701 in malignant ascites (7 cohorts), sponsored by Wuhan YZY Biopharma Co., Ltd. Primary endpoints: Maximum Tolerated Dose at Day 28 and Incidence of Adverse Events up to 6 months. Started Sep 2018; status: completed.
02
Drugs
M701
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT04501744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501744.